Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1839]

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Implementation of genetic testing in breast cancer patients

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Implementation of genetic testing in breast cancer patients ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in...

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Breast cancer screening and treatment in Brazil

Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre...

Breast cancer screening and treatment in Brazil ( Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre, Brazil )

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast...

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Circulating tumour DNA used to predict disease recurrence for early triple...

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

Oral paclitaxel with encequidar in metastatic breast cancer

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Oral paclitaxel with encequidar in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )

Pathologic complete response rates improved with the neoadjuvant and adjuvant...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Breast cancer prevention in high-risk post-menopausal women

Prof Jack Cuzick - Queen Mary University of London, London, UK

Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

More from ecancer